CTI BioPharma Corp. CTIC
9.10 0.00 (+0.00%)
Jun 23, 2023, 3:58 PM EDT
9.09 Day range 9.10
52-week range unavailable
- Market cap
- 1.20B
- Revenue (ttm)
- 75.77M
- Profit margin
- -91.38%
- Shares out
- 131.88M
- Forward P/E
- 101.00
- Volume
- 5.56M
- Open
- 9.10
- Previous close
- 9.10
- Day's range
- 9.09 – 9.10
- Beta
- 0.83
- Analysts
- Buy
- Price target
- 10.37 (+14.0%)
- Earnings date
- Aug 14, 2023
2Y +6.30 (+225.81%)
Key statistics
- Enterprise value
- 1.26B
- PEG ratio
- 0.00
- Price / sales
- 15.82
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 950.80%
- Free cash flow
- -85.26M
- Total cash
- 59.01M
- Total debt
- 118.29M
- Return on equity
- 0.00%
- Short % of float
- 15.18%
- 50-day average
- 7.63
- 200-day average
- 5.87
Analyst view
Consensus: buy
Buy
Price target (mean) 10.37 +14.0% upside
Now 9.10
- Target (low)
- 9.00
- Target (mean)
- 10.37
- Target (high)
- 13.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate -0.08.
Financials — quick view
CTIC Revenue — quarterly 24.12M
CTIC Net income — quarterly -13.42M
CTIC EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 14, 2023 | Jun 1, 2023 | -0.08 | — | — | — |
| Mar 6, 2023 | Dec 1, 2022 | -0.09 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.15 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.20 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.35 | — | — | — |
| Mar 31, 2022 | Dec 1, 2021 | -0.28 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 24, 2023 | JMP Securities | main | — | Market Perform |
| May 16, 2023 | SVB Leerink | down | Outperform | Market Perform |
| May 15, 2023 | Stifel | down | Buy | Hold |
| May 11, 2023 | JMP Securities | down | Market Outperform | Market Perform |
| May 11, 2023 | Needham | down | Buy | Hold |
| Apr 19, 2023 | Needham | reit | — | Buy |
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ctibiopharma.com
News
Sobi completes acquisition of CTI BioPharma Corp. 
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp. 
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC 
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders 
Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp. 
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023 
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023 
Earnings Scheduled For May 11, 2023 
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC 
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on CTIC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BVF PARTNERS L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 8, 2022 | 0 |
| CRAIG ADAM R | Chief Executive Officer | Sale | Jan 23, 2023 | 29,440 |
| FONG JAMES K | Officer | Sale | Jan 23, 2023 | 3,565 |
| KIRSKE DAVID H. SR | Chief Financial Officer | Sale | Jan 2, 2023 | 17,127 |
| LOVE RICHARD L | Director | Sale | Sep 28, 2017 | 73,718 |
| METZGER MICHAEL A | Director | Sale | Nov 7, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| State Street Corporation | 9.43% | 12,437,278 | 113.05M | Mar 30, 2023 |
| Rubric Capital Management LP | 6.80% | 8,963,256 | 81.48M | Mar 30, 2023 |
| BVF Inc. | 6.68% | 8,813,021 | 80.11M | Mar 30, 2023 |
| Blackrock Inc. | 5.39% | 7,102,626 | 64.56M | Mar 30, 2023 |
| Stonepine Capital Management, LLC | 4.96% | 6,535,674 | 59.41M | Mar 30, 2023 |
| Marshall Wace LLP | 4.52% | 5,960,103 | 54.18M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.47% | 12,486,890 | 113.51M | Feb 27, 2023 |
| Vanguard Total Stock Market Index Fund | 2.64% | 3,484,904 | 31.68M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.69% | 2,228,127 | 20.25M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 1.02% | 1,346,944 | 12.24M | Dec 30, 2022 |
| Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh | 0.87% | 1,153,365 | 10.48M | Mar 30, 2023 |
| TIAA-CREF Funds-Quant Small Cap Equity Fund | 0.75% | 988,140 | 8.98M | Jan 30, 2023 |